Luca Longhi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2344206/publications.pdf

Version: 2024-02-01

		279798	377865
37	2,590	23	34
papers	citations	h-index	g-index
39	39	39	2969
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	EEG reactivity predicts recovery of consciousness in patients with acute brain injury and signs of intracranial hypertension. Clinical Neurophysiology, 2019, 130, 1741-1742.	1.5	O
2	Human brain trauma severity is associated with lectin complement pathway activation. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 794-807.	4.3	24
3	Pharmacological inhibition of mannose-binding lectin ameliorates neurobehavioral dysfunction following experimental traumatic brain injury. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 938-950.	4.3	35
4	Implementation of continuous qEEG in two neurointensive care units by intensivists: a feasibility study. Intensive Care Medicine, 2017, 43, 1067-1068.	8.2	24
5	Cardiac Function Following Traumatic Brain Injury. Critical Care Medicine, 2017, 45, e1193-e1194.	0.9	2
6	Intracranial Pressure After Subarachnoid Hemorrhage*. Critical Care Medicine, 2015, 43, 168-176.	0.9	117
7	Mannose-Binding Lectin Is Expressed After Clinical and Experimental Traumatic Brain Injury and Its Deletion Is Protective*. Critical Care Medicine, 2014, 42, 1910-1918.	0.9	49
8	Changes of the GPR17 receptor, a new target for neurorepair, in neurons and glial cells in patients with traumatic brain injury. Purinergic Signalling, 2013, 9, 451-462.	2.2	54
9	Tumor Necrosis Factor in Traumatic Brain Injury: Effects of Genetic Deletion of p55 or p75 Receptor. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 1182-1189.	4.3	62
10	Volatile Anesthetics Following Subarachnoid Hemorrhage. Critical Care Medicine, 2013, 41, e37.	0.9	1
11	Mannose-binding lectin deficiency reduces functional deficits and histological damage after experimental traumatic brain injury. Immunobiology, 2012, 217, 1185.	1.9	0
12	Human umbilical cord blood mesenchymal stem cells protect mice brain after trauma*. Critical Care Medicine, 2011, 39, 2501-2510.	0.9	130
13	Long-lasting protection in brain trauma by endotoxin preconditioning. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 1919-1929.	4.3	83
14	Cerebrospinal fluid pentraxin 3 early after subarachnoid hemorrhage is associated with vasospasm. Intensive Care Medicine, 2011, 37, 302-309.	8.2	25
15	The race for biomarkers in traumatic brain injury: What science promises and the clinicians still expect*. Critical Care Medicine, 2010, 38, 318-319.	0.9	1
16	C1-inhibitor attenuates neurobehavioral deficits and reduces contusion volume after controlled cortical impact brain injury in mice*. Critical Care Medicine, 2009, 37, 659-665.	0.9	116
17	c-Jun N-Terminal Kinase Pathway Activation in Human and Experimental Cerebral Contusion. Journal of Neuropathology and Experimental Neurology, 2009, 68, 964-971.	1.7	38
18	Impact of traumatic lesions on intracerebral probe positioning. Intensive Care Medicine, 2008, 34, 1158-1159.	8.2	0

#	Article	IF	Citations
19	NICEM consensus on neurological monitoring in acute neurological disease. Intensive Care Medicine, 2008, 34, 1362-1370.	8.2	115
20	Time Course of Intracranial Hypertension after Traumatic Brain Injury. Journal of Neurotrauma, 2007, 24, 1339-1346.	3.4	95
21	Monitoring brain tissue oxygen tension in brain-injured patients reveals hypoxic episodes in normal-appearing and in peri-focal tissue. Intensive Care Medicine, 2007, 33, 2136-2142.	8.2	105
22	Temporal Window of Vulnerability to Repetitive Experimental Concussive Brain Injury. Neurosurgery, 2005, 56, 364-374.	1.1	274
23	Enhanced Neurofibrillary Tangle Formation, Cerebral Atrophy, and Cognitive Deficits Induced by Repetitive Mild Brain Injury in a Transgenic Tauopathy Mouse Model. Journal of Neurotrauma, 2005, 22, 1134-1141.	3.4	120
24	Stem cell transplantation as a therapeutic strategy for traumatic brain injury. Transplant Immunology, 2005, 15, 143-148.	1.2	49
25	Neurodegeneration and neuroprotective strategies after traumatic brain injury. Drug Discovery Today Disease Mechanisms, 2005, 2, 409-418.	0.8	10
26	Ex VivoGene Therapy Using Targeted Engraftment of NGF-Expressing Human NT2N Neurons Attenuates Cognitive Deficits Following Traumatic Brain Injury in Mice. Journal of Neurotrauma, 2004, 21, 1723-1736.	3.4	82
27	Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. Journal of Neurochemistry, 2004, 90, 1541-1541.	3.9	1
28	Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. Journal of Neurochemistry, 2004, 90, 758-764.	3.9	147
29	Motor and cognitive function evaluation following experimental traumatic brain injury. Neuroscience and Biobehavioral Reviews, 2004, 28, 365-378.	6.1	258
30	Moving from macro- to microcirculation in head injury*. Critical Care Medicine, 2004, 32, 1429-1430.	0.9	4
31	Hyperoxia in head injury. Current Opinion in Critical Care, 2004, 10, 105-109.	3.2	22
32	Genetically Modified NT2N Human Neuronal Cells Mediate Long-Term Gene Expression as CNS Grafts In Vivo and Improve Functional Cognitive Outcome Following Experimental Traumatic Brain Injury. Journal of Neuropathology and Experimental Neurology, 2003, 62, 368-380.	1.7	84
33	Apolipoprotein E4 Influences Amyloid Deposition But Not Cell Loss after Traumatic Brain Injury in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2002, 22, 10083-10087.	3.6	108
34	Brain Oxygen Tension, Oxygen Supply, and Oxygen Consumption During Arterial Hyperoxia in a Model of Progressive Cerebral Ischemia. Journal of Neurotrauma, 2001, 18, 163-174.	3.4	31
35	A Review and Rationale for the Use of Genetically Engineered Animals in the Study of Traumatic Brain Injury. Journal of Cerebral Blood Flow and Metabolism, 2001, 21, 1241-1258.	4.3	42
36	Mild head injury increasing the brain's vulnerability to a second concussive impact. Journal of Neurosurgery, 2001, 95, 859-870.	1.6	278

ARTICLE IF CITATIONS

37 Multimodality monitoring., 0,, 119-127. 0